Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
- Written by ACN Newswire - Press Releases
Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,
Read more //?#
.
From Check-in to Touchdown: How AI and smarter systems are transforming the travel industry
Richard Valente, VP of Customer Experience Strategy at TP in Australia, explores how IT-BPM outsourcing is revolutionising the travel sector throu...
Online Christmas shoppers fund climate and biodiversity projects via HealthPost's Click Sphere for Good initiative
Online shoppers with HealthPost’s Flora & Fauna have made 11,000 contributions towards climate and biodiversity projects when ordering parcel ...
US landmark settlement protects SMEs, highlighting flaws in the RBA's proposed blanket card surcharging ban for Australia
Aussie SMEs warn RBA not to ignore global trends, with the current sledgehammer approach threatening business viability and increasing inflation ...
Thryv Australia named Employer of Choice for third consecutive year at Australian Business Awards
Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, has been awarded the Employer of ...
RogersDigital.com Announces the Launch of TheBulletin.au, a Destination for Business, Policy and Financial Insight
RogersDigital.com has announced the launch of TheBulletin.au, a new national digital publication designed to deliver sharp, data-driven reporting ...
Controlling business spend is helping finance leaders to forecast with confidence
Forecasting has always been central to financial planning; however, traditional methods based on historical trends are no longer enough. Economic ...